(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 112.82% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Alvotech's revenue in 2024 is $93,382,000.On average, 2 Wall Street analysts forecast ALVO's revenue for 2024 to be $85,159,393,375, with the lowest ALVO revenue forecast at $80,046,553,200, and the highest ALVO revenue forecast at $90,272,500,371. On average, 2 Wall Street analysts forecast ALVO's revenue for 2025 to be $159,697,409,605, with the lowest ALVO revenue forecast at $146,752,014,200, and the highest ALVO revenue forecast at $172,643,071,833.
In 2026, ALVO is forecast to generate $242,530,916,966 in revenue, with the lowest revenue forecast at $242,530,916,966 and the highest revenue forecast at $242,530,916,966.